Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents

Inclusion Criteria:

• Patients with stable angina, unstable angina, or non-ST elevation myocardial infarction.

  • Patients with multivessel coronary artery disease including significant stenotic lesion* in the right coronary artery and also including left main stem disease.
  • Patients who will be referred for CABG.
  • Patients with significant stenotic lesion in the right coronary artery amenable to PCI.
  • Patients who can take DAPT medications.
  • Patients who provided written informed consent. * Significant stenotic lesion means a condition where fractional flow reserve (FFR) is lower than 0.80 or visually confirmed stenosis is at least 75%.

Exclusion Criteria:

• • Patients with ST elevation myocardial infarction occurring within 24 hours before enrollment.

  • Patients who previously underwent CABG.
  • Patients who are at high risk of receiving CABG.
  • Patients who need simultaneous surgery such as valve surgery other than CABG.
  • Patients with a life expectancy of 1 year or shorter due to co-morbidities.
  • Patients with a history of cerebral infarction within the last 6 months.
  • Patients with congestive cardiac failure of NYHA 3 or higher.
  • Patients with unstable hemodynamics at enrollment.
  • Patients with right coronary artery disease that is chronic total occlusion and difficult to treat with PCI (J-CTO score of ≥ 23).
  • Patients receiving long-term dialysis.
  • Patients who are allergic to antiplatelet agent.
  • Patients who are critically allergic to contrast media.
  • Patients who are allergic to any DES component.